VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemes
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
Earnings
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Pharma & Energy
LLY vs NVOJNJ vs PFEXOM vs CVX
Compare Any Stocks...
WatchlistInsider
ScreenerThemes
Earnings
WatchlistInsider
CUPR
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
CUPRCuprina Holdings (Cayman) Limited Class A Ordinary Shares
$5.74$15M
Overview & Verdict
Overview
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice HistoryTechnical Analysis
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Ownership
Holders

CUPR logoCuprina Holdings (Cayman) Limited Class A Ordinary Shares(CUPR)Earnings, Financials & Key Ratios

CUPR•NASDAQ
$5.74
Price updated Jul 7, 2026
SectorHealthcareIndustryBiotechnologySub-IndustryCommercial Specialty Pharma
AboutCuprina Holdings (Cayman) Limited is a Singapore-based biomedical and biotechnology company dedicated to developing and commercializing innovative products for managing chronic wounds. The company manufactures and distributes medical-grade sterile blowfly larvae bio-dressing products under the MEDIFLY brand, used as a biological debridement tool for chronic wounds. Additionally, Cuprina operates in the health and beauty sectors, offering cosmeceutical products.Show more
  • Revenue$50K+3.3%
  • EBITDA-$5M-182.6%
  • Net Income-$5M-199.5%
  • EPS (Diluted)-1.84-220.8%
  • Gross Margin-1.29%+79.3%
  • EBITDA Margin-9081.41%-173.7%
  • Operating Margin-9154.62%-168.9%
  • Net Margin-9366.75%-190.0%
  • ROE-1569.05%

CUPR Price & Volume

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) stock price & volume — 10-year historical chart

Loading chart...

Nascent Revenue Fails To Offset Operational Burn

Investment Thesis • Updated N/A

VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Adequate
Cash Flow:Burning
Primary Risk:Commercial scale and liquidity

Key Thesis Takeaways

  • Cuprina Holdings faces a challenging path to commercial viability as its specialized MEDIFLY production model struggles to scale beyond a $50,000 revenue base.
  • The firm's extreme operating margin of -9154% suggests that current administrative and research costs are entirely decoupled from its limited clinical footprint.
  • Investors should remain cautious as the company attempts to navigate the high-risk transition from early-stage development to a sustainable, profitable business model.

Verdict Logic

the company's P/S ratio of 370.38 and extreme operating losses suggest that the current valuation is not supported by its nascent $50,000 revenue generation.

CUPR Growth Metrics

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-
3 Years-4.12%
TTM-

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM-

Return on Capital

10 Years-835.65%
5 Years-835.65%
3 Years-835.65%
Last Year-835.65%

Latest CUPR News

Recent stock market news and headlines for Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)

Benzinga·Jun 16, 2026
Cuprina Holdings Falls 22% After 112% Rally — Here's Why CUPR Stock Is Trending

Cuprina stock surged 112% after FDA clearance for MEDIFLY Maggots before falling sharply in after-hours trading.

Peers Comparison

Key metrics vs top competitors for Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
CUPR logoCUPRCuprina Holdings (Cayman) Limited Class A Ordinary SharesCurrent
$5.74$15.39M-4.033.26%-9366.75%-1569.05%—
HROW logoHROWHarrow Health, Inc.
$46.15$1.72B-329.6436.41%-5.57%-33.92%—
PAHC logoPAHCPhibro Animal Health Corporation
$33.12$1.34B27.8327.37%6.35%29.49%—
ELAN logoELANElanco Animal Health Incorporated
$24.64$12.31B-52.436.22%-4.95%-3.64%—
ZTS logoZTSZoetis Inc.
$76.29$31.98B12.672.28%27.79%62.41%—
PCRX logoPCRXPacira BioSciences, Inc.
$25.82$1.02B161.383.63%1.27%1.31%—

Compare CUPR vs Peers

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs HROW

Most directly comparable listed peer for CUPR.

Scale Benchmark

vs IDXX

Larger-name benchmark to compare CUPR against a more recognizable public peer.

Peer Set

Compare Top 5

vs HROW, PAHC, ELAN, ZTS

Get notified when CUPR posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

CUPR Frequently Asked Questions

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Cuprina Holdings (Cayman) Limited Class A Ordinary Shares's revenue?

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) reported $0.0M in revenue for fiscal year 2025. This represents a 15% decrease from $0.1M in 2021.

How fast is Cuprina Holdings (Cayman) Limited Class A Ordinary Shares growing?

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) grew revenue by 3.3% over the past year. Growth has been modest.

Is CUPR profitable?

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) reported a net loss of $4.7M for fiscal year 2025.

Dividend & Returns
What is CUPR's return on equity?

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) has a return on equity (ROE) of -1569.1%. Negative ROE indicates the company is unprofitable.

What is Cuprina Holdings (Cayman) Limited Class A Ordinary Shares's free cash flow?

Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) had negative free cash flow of $9.2M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in CUPR back in 2021?

Total return calculator · dividends reinvested · 5+ years of data

See returns →